Skip to content

Comparative Study of GangTrainer GT1, Lokomat and Conventional Physiotherapy

Robot Assisted Therapy for Acute Stroke Patients: a Comparative Study of GangTrainer GT I, Lokomat System and Conventional Physiotherapy

Status
Suspended
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01146587
Acronym
galop
Enrollment
120
Registered
2010-06-17
Start date
2010-08-31
Completion date
2016-02-29
Last updated
2015-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke, Acute

Keywords

Stroke, Robotics, Gait, Rehabilitation

Brief summary

The GangTrainer GT I and the Lokomat have proven their effectiveness on stroke Patients, but a comparison on the same controlled study population has not been made so far. Aim of the study will not only be to establish which device will work better on acute, non ambulatory stroke Patients in terms of regain of gait ability and motor function, but also clinical matters, like the efficacy of the treatment period. As a result of the trial it should be highlighted which kind of therapy has to be suggested for Patients comparable to the study population. A significant better outcome of one device in regard to the other will suggest to use one device more than the other for future treatments.

Detailed description

A total of 120 Patients will be enroled in the study and divided into 2 treatment and 1 control group. Enroled Patients will all be first supratentorial non ambulatory stroke patients (ischaemic, haemorrhagic or ICH) with a hemiparesis and stroke onset from 3 - 12 weeks. Theywill undergo either robotic treatment with the Gangtrainer GT1 or the Lokomat in one of the 2 treatment groups for 30 minutes of gross therapy time every workday for a 8 weeks period if they are in the treatment group, or conventional physiokinetherapy for 30 minutes of gross therapy time every workday for a 8 weeks period if they are in the control group. Primary outcome will be the Functional Ambulation Category (FAC) assessed at enrolment, after 4 weeks after 8 weeks and at 6 months follow up.

Interventions

DEVICEGangTrainer GT1

30 minutes of treatment on the GangTrainer GT1 and 30 minutes of Conventional Physiotherapy every workday for 8 weeks

DEVICELokomat

30 minutes of treatment on the Lokomat and 30 minutes of Conventional Physiotherapy every workday for 8 weeks

OTHERConventional Physiotherapy

60 minutes of Conventional Physiotherapy every workday for 8 weeks

Sponsors

Privatklinik Villa Melitta
CollaboratorOTHER
Hochzirl Hospital
CollaboratorOTHER
Krankenhaus Bozen
CollaboratorOTHER
Krankenhaus Brixen
CollaboratorOTHER
Krankenhaus Meran
CollaboratorOTHER
Krankenhaus Bruneck
CollaboratorOTHER
Claudiana Landesfachhochschule
CollaboratorOTHER
Research Department for Neurorehabilitation South Tyrol
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 79 Years
Healthy volunteers
No

Inclusion criteria

* First supratentorial stroke (ischaemic, haemorrhagic or ICH) resulting in a hemiparesis * Interval from stroke 3 - 12 weeks * Non ambulatory (FAC \< 3) * Free sitting on bedside for 1 minute, both feet on the floor, ev. holding on bedside by hands * Barthel Index 25 - 65

Exclusion criteria

* Unstable cardiovascular system (in case of doubt, only after approval by a internist) * Manifested heart diseases like labile compensated cardiac insufficiency (NYHA III), angina pectoris, myocardial infarction 120 days before study onset, cardiomyopathy, severe cardiac arrhythmia * Severe joint misalignment (severe constriction of movement for hip, knee and/or ankle: more than 20° fixed hip and knee extension deficit, or more than 20° fixed plantar flexion of the ankle * Severe cognitive dysfunction, which does not allow for comprehension of the aims of this study * Severe neurological or orthopaedic diseases (like polio, Parkinson´s disease), which massively affect the mobility * Deep vein thrombosis * Severe osteoporosis * Malignant tumour diseases

Design outcomes

Primary

MeasureTime frame
Functional Ambulation Category (FAC)after 8 weeks

Secondary

MeasureTime frame
Rivermead Mobility Index (RMI)at week 1
10 metres Walking Testat week 1
6 Minutes Walking Test on the Floorat week 1
6 Minutes Walking Test on the Treadmill with Body Weight Supportat week 1
Medical Research Council (MRC)at week 1
Barthel Index (BI)at week 1
Rivermead Visual Gait Assessment (RVGA)at week 1
EuroQol 5 Dimensions (EQ-5D)at week 1
modified emory Functional Ambulation Profile (meFAP)at week 1
Functional Ambulation Category (FAC)at week 1
Modified Ashworth Scale (mAS)at week 1

Countries

Austria, Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026